United Therapeutics Corporation (UTHR) Receives Price Target

United Therapeutics Corporation (UTHR) stock is expected to deviate a maximum of $40.26 from the average target price of $134.63 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $229 and the most muted being $95.

United Therapeutics Corporation (UTHR) : Zacks Investment Research ranks United Therapeutics Corporation (UTHR) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.5, which indicates as a Buy.


Also, JP Morgan maintains their rating on the shares of United Therapeutics Corporation (NASDAQ:UTHR). The current rating of the shares is Neutral. Equity Analysts at the Firm lowers the price target to $129 per share from $145 per share. The rating by the firm was issued on July 29, 2016.

United Therapeutics Corporation (NASDAQ:UTHR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $122.75 and $121.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $123.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $123.21, notching a gain of 0.76% for the day. The total traded volume was 420,082 . The stock had closed at $122.28 on the previous day.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.